Literature DB >> 22411971

Short-term statin administration in hypercholesterolaemic rabbits resistant to postconditioning: effects on infarct size, endothelial nitric oxide synthase, and nitro-oxidative stress.

Ioanna Andreadou1, Dimitrios Farmakis, Eftihios Prokovas, Fragiska Sigala, Anastasia Zoga, Katerina Spyridaki, Apostolos Papalois, Andreas Papapetropoulos, Maria Anastasiou-Nana, Dimitrios Th Kremastinos, Efstathios K Iliodromitis.   

Abstract

AIMS: The effectiveness of postconditioning (POC) in hypercholesterolaemia is in dispute. We investigated the effects of 3-day lipophilc (simvastatin) or hydrophilic (pravastatin) statin treatment, without or with POC in normocholesterolaemic (Norm) and hypercholesterolaemic (Chol) rabbits. METHODS AND
RESULTS: Norm or Chol rabbits were subjected to 30 min ischaemia and randomized in two series of 12 groups each: control, simvastatin (Sim), pravastatin (Prav), POC, Sim-POC, Prav-POC, Chol, Sim-Chol, Prav-Chol, POC-Chol, Sim-POC-Chol, Prav-POC-Chol. After ischaemia, rabbits of the first series underwent 3 h reperfusion, followed by infarct size, total cholesterol, and low density lipoprotein plasma level evaluation; animals of the second series underwent 10 min reperfusion followed by tissue sampling for nitrotyrosine (NT), malondialdehyde, endothelial nitric oxide synthase (eNOS), and Akt analyses. N-nitro-l-arginine methylester (L-NAME) was given in two additional groups (POC-L-NAME and Prav-Chol-L-NAME) for infarct size assessment. All interventions reduced infarction in Norm (24.3 ± 1.3, 25.9 ± 2.8, 27.9 ± 3.1, 23.3 ± 2.3, and 33.4 ± 2.5%, in POC, Sim, Prav, Sim-POC, and Prav-POC groups, respectively, vs. 49.3 ± 1.9% in control, P < 0.05), but only Prav did so in Chol animals (25.7 ± 3.3 and 25.3 ± 3.9% in Prav-Chol and Prav-POC-Chol vs. 50.9 ± 1.7, 44.8 ± 4.3, 41.5 ± 3.5, and 49.3 ± 5.5% in Chol, Sim-Chol, POC-Chol, and Sim-POC-Chol, respectively, P < 0.05). L-NAME abolished the infarct size-limiting effect of POC and Prav-Chol. Prav induced the greatest reduction in NT, while it was the only intervention that increased myocardial eNOS and Akt in Chol rabbits (P < 0.05 vs. all others).
CONCLUSION: Prav, in contrast to same-dose Sim or POC, reduces infarction in Chol rabbits independently of lipid lowering, potentially through eNOS activation and nitro-oxidative stress attenuation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22411971     DOI: 10.1093/cvr/cvs121

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  16 in total

1.  Cardioprotection by H2S engages a cGMP-dependent protein kinase G/phospholamban pathway.

Authors:  Sofia-Iris Bibli; Ioanna Andreadou; Athanasia Chatzianastasiou; Christos Tzimas; Despina Sanoudou; Evangelia Kranias; Peter Brouckaert; Ciro Coletta; Csaba Szabo; Dimitrios Th Kremastinos; Efstathios K Iliodromitis; Andreas Papapetropoulos
Journal:  Cardiovasc Res       Date:  2015-04-13       Impact factor: 10.787

Review 2.  Effect of hypercholesterolaemia on myocardial function, ischaemia-reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning.

Authors:  Ioanna Andreadou; Efstathios K Iliodromitis; Antigone Lazou; Anikó Görbe; Zoltán Giricz; Rainer Schulz; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2017-02-08       Impact factor: 8.739

Review 3.  Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection.

Authors:  Hans Erik Bøtker; Derek Hausenloy; Ioanna Andreadou; Salvatore Antonucci; Kerstin Boengler; Sean M Davidson; Soni Deshwal; Yvan Devaux; Fabio Di Lisa; Moises Di Sante; Panagiotis Efentakis; Saveria Femminò; David García-Dorado; Zoltán Giricz; Borja Ibanez; Efstathios Iliodromitis; Nina Kaludercic; Petra Kleinbongard; Markus Neuhäuser; Michel Ovize; Pasquale Pagliaro; Michael Rahbek-Schmidt; Marisol Ruiz-Meana; Klaus-Dieter Schlüter; Rainer Schulz; Andreas Skyschally; Catherine Wilder; Derek M Yellon; Peter Ferdinandy; Gerd Heusch
Journal:  Basic Res Cardiol       Date:  2018-08-17       Impact factor: 17.165

Review 4.  Metabolic syndrome, aging and involvement of oxidative stress.

Authors:  Francesca Bonomini; Luigi Fabrizio Rodella; Rita Rezzani
Journal:  Aging Dis       Date:  2015-03-10       Impact factor: 6.745

Review 5.  Hyperlipidaemia and cardioprotection: Animal models for translational studies.

Authors:  Ioanna Andreadou; Rainer Schulz; Lina Badimon; Adriana Adameová; Petra Kleinbongard; Sandrine Lecour; Panagiota-Efstathia Nikolaou; Ines Falcão-Pires; Gemma Vilahur; Nicholas Woudberg; Gerd Heusch; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2020-01-17       Impact factor: 8.739

Review 6.  The role of gasotransmitters NO, H2S and CO in myocardial ischaemia/reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning.

Authors:  Ioanna Andreadou; Efstathios K Iliodromitis; Tienush Rassaf; Rainer Schulz; Andreas Papapetropoulos; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2014-09-23       Impact factor: 8.739

Review 7.  Postconditioning signalling in the heart: mechanisms and translatability.

Authors:  Justin S Bice; Gary F Baxter
Journal:  Br J Pharmacol       Date:  2014-12-15       Impact factor: 8.739

Review 8.  The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration.

Authors:  Rebecca Hutcheson; Petra Rocic
Journal:  Exp Diabetes Res       Date:  2012-07-09

9.  Ischemia/Reperfusion injury, its mechanisms, and prevention.

Authors:  Maciej Kosieradzki; Johann Pratschke; Jerzy Kupiec-Węgliński; Wojciech Rowiński
Journal:  J Transplant       Date:  2012-12-26

10.  Activation of cGMP/protein kinase G pathway in postconditioned myocardium depends on reduced oxidative stress and preserved endothelial nitric oxide synthase coupling.

Authors:  Javier Inserte; Victor Hernando; Úrsula Vilardosa; Elena Abad; Marcos Poncelas-Nozal; David Garcia-Dorado
Journal:  J Am Heart Assoc       Date:  2013-01-02       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.